ChatGPT is Poised to Disrupt Medical Affairs
With a multibillion dollar investment from Microsoft and already 4 authorship credits on PubMed, ChatGPT is poised to disrupt Medical Affairs.
With a multibillion dollar investment from Microsoft and already 4 authorship credits on PubMed, ChatGPT is poised to disrupt Medical Affairs.
MAPS speaks with Tim Mikhelashvili, CEO and Co-Founder of Amedea Pharma, and the winners of his Medical Affairs Olympics Competition, the CEOs of Discreedly and Inphronesis.
In today’s episode, we’re talking with Joseph Zabinski, PhD, Senior Director, AI & Personalized Medicine at OM1 about Artificial Intelligence — specifically about how AI can accelerate diagnosis and treatment.
This Webinar aims to achieve awareness on challenges and solutions when listening to, and interacting with, Digital Opinion Leaders.
In this our second episode this season, we’ll be discussing open access in medical publishing from the biopharma perspective.
In this webinar, experts will lay the foundation of what conversational AI is, best and emerging practices, provide use cases, and discuss regulatory and legal considerations.
After this webinar, attendees will walk away with a critical understanding of artificial intelligence, best practices for building trust in AI, and real-world applications for Medical Affairs.
This webinar will introduce a practical view on how to develop Medical Affairs omnichannel strategies within your organization
Digitalization offers Medical Affairs teams the opportunity to rethink strategy and actions across the lifecycle of traditional and nontraditional products.
Here John Pracyk, MD, PhD, MBA, MAPS President of the Americas Region speaks with some of the top Medical Affairs leaders from Johnson & Johnson as they share their perspective on the impact of Digital on Healthcare.
